News Related to Modifier Gene Therapy

Related coverage linked through entity extraction aliases.

Ocugen to Report Q4 and Full Year 2025 Results on March 4, 2026

Mar 04, 2026

Ocugen will host a conference call on March 4, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and provide a business update, with a pre-market earnings announcement the same day.

Ocugen Completes Enrollment in Phase 3 Gene Therapy Trial for Retinitis Pigmentosa

Mar 03, 2026

Ocugen has completed enrollment of 140 patients in its Phase 3 liMeliGhT trial for OCU400, a gene therapy for retinitis pigmentosa. Topline data expected in Q1 2027 could support potential approval later that year.